The global wearable biosensors in clinical trials market is driven by the growing need for real-time monitoring in clinical research, especially in chronic disease management such as diabetes and cardiovascular diseases. With diabetes expected to affect 700 million people by 2045 and cardiovascular diseases impacting over 40% of adults globally, wearable biosensors are crucial for continuous patient data collection and remote monitoring in clinical trials. These devices enhance trial accuracy, improve patient compliance, and reduce costs, making them integral to drug development, particularly in personalized treatments for conditions such as cancer.
